FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma. The test was approved in the US last year for screening plasma specimens from blood donors and, earlier this year, received the CE Mark for screening source plasma.

"Roche is committed to providing the broadest coverage and an easy-to-use menu of screening tests to ensure the highest safety of blood and plasma products," said Daniel O'Day, head of Roche Molecular Diagnostics, the business area of Roche Diagnostics that developed the test. "The expanded use of our multiplex test, which has been widely adopted and has demonstrated excellent performance worldwide, is one more step toward that goal. We are pleased to introduce this new use of the cobas® TaqScreen MPX Test in the US as we continue to further invest in solutions for this critical industry."

Human plasma is fractionated into its components, such as immunoglobulins, albumin, and clotting factors, which have many therapeutic uses. These include treatment of chronic and hereditary diseases and disorders such as hemophilia and primary immunodeficiency diseases. Plasma is also used to treat patients who have suffered severe burns or trauma, and during major surgery.

Many countries have implemented Nucleic Acid Technology (NAT) testing in order to further ensure the safety of blood and blood products. In Western Europe and North America, routine NAT testing, which can detect HIV-1 and HCV in the early stages of infection, has reduced the risk of transfusion-transmitted HIV-1 and HCV infections to negligible levels. The importance of hepatitis B virus in transfusion-transmitted diseases is increasingly being recognized and NAT screening for HBV is being implemented in some countries.

The cobas® TaqScreen MPX Test runs on the fully automated, real-time PCR cobas s 201 system, designed to increase processing efficiency with a unique modular design and ready-to-use reagents.

The cobas s 201 system has the capability of running multiple channels using multi-dye technology, enabling simultaneous detection of several viruses. Roche is developing another multi-dye assay on the same platform, the cobas® TaqScreen DPX test, that is designed to simultaneously provide a quantitative result for B19 virus and a qualitative result for hepatitis A virus.

"As a stand-alone PCR system the cobas s 201 system and cobas® TaqScreen MPX Test for HBV, HIV and HCV, provides a simple user interface while improving process control and lab efficiencies," said Douglas Lee, PhD, Sr. Director Pathogen Safety and Research, Talecris Biotherapeutics, one of the largest fractionators in the US and a clinical trial site for the cobas® TaqScreen MPX Test.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Roche Sequencing and Life Science. (2019, June 19). FDA approves additional intended use of Roche's cobas TaqScreen MPX Test. News-Medical. Retrieved on October 06, 2024 from https://www.news-medical.net/news/20091202/FDA-approves-additional-intended-use-of-Roches-cobas-TaqScreen-MPX-Test.aspx.

  • MLA

    Roche Sequencing and Life Science. "FDA approves additional intended use of Roche's cobas TaqScreen MPX Test". News-Medical. 06 October 2024. <https://www.news-medical.net/news/20091202/FDA-approves-additional-intended-use-of-Roches-cobas-TaqScreen-MPX-Test.aspx>.

  • Chicago

    Roche Sequencing and Life Science. "FDA approves additional intended use of Roche's cobas TaqScreen MPX Test". News-Medical. https://www.news-medical.net/news/20091202/FDA-approves-additional-intended-use-of-Roches-cobas-TaqScreen-MPX-Test.aspx. (accessed October 06, 2024).

  • Harvard

    Roche Sequencing and Life Science. 2019. FDA approves additional intended use of Roche's cobas TaqScreen MPX Test. News-Medical, viewed 06 October 2024, https://www.news-medical.net/news/20091202/FDA-approves-additional-intended-use-of-Roches-cobas-TaqScreen-MPX-Test.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Roche launched world's first COVID-19 PCR test two years ago